CV Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

2 Analyst Rating

Wall Street analysts forecast CV stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CV is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 13.790

Low

5.00

Averages

6.00

High

7.00

Current: 13.790

Low

5.00

Averages

6.00

High

7.00

Roth Capital

NULL

Buy

initiated

2025-11-04

Reason

Roth Capital

Price Target

2025-11-04

initiated

NULL

Buy

Reason

Roth Capital resumed coverage of CapsoVision with a Buy rating and $7 price target. The firm says the two label expansions in December 2024, to include pediatrics as young as two and remote ingestions, will help to accelerate adoption of the company's "best-in-class" device. It sees clearance of Gen 1 CapsoCam Colon as well as submissions for CapsoVision's small bowel artificial intelligence module as additional catalysts for the shares.

Roth Capital

Jason Wittes

Buy

initiated

2025-07-28

Reason

Roth Capital

Jason Wittes

Price Target

2025-07-28

initiated

Buy

Reason

Roth Capital analyst Jason Wittes initiated coverage of CapsoVision with a Buy rating and $6 price target. The firm believes the company is progressing advanced imaging and artificial intelligence implementation with its capsule endoscopy platform for gastrointestinal screening and diagnosis. CapsoVision is positioned for 19.5% growth in 2025 with its initial small bowel indication, and also recently submitted 510(k) approval for the much larger colon indication, the analyst tells investors in a research note. It sees this boosting revenue growth in 2026.

Benchmark

NULL -> Speculative Buy

initiated

2025-07-28

Reason

Benchmark

Price Target

2025-07-28

initiated

NULL -> Speculative Buy

Reason

Benchmark initiated coverage of CapsoVision with a Speculative Buy rating and $5 price target.

Benchmark

Speculative Buy

initiated

2025-07-28

Reason

Benchmark

Price Target

2025-07-28

initiated

Speculative Buy

Reason

As previously reported, Benchmark initiated coverage of CapsoVision with a Speculative Buy rating and $5 price target. The company's CapsoCam Plus for small bowel applications has been gaining market share with its differentiated features, notes the analyst, who sees the potential for additional long-term growth coming from international expansion and the ability to screen for multiple cancers simultaneously. The company will soon introduce AI-assisted image reading and a version of the product designed for the large intestine, the analyst noted.

Valuation Metrics

The current forward P/E ratio for CapsoVision Inc (CV.O) is -24.76, compared to its 5-year average forward P/E of -9.51. For a more detailed relative valuation and DCF analysis to assess CapsoVision Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.51

Current PE

-24.76

Overvalued PE

-5.67

Undervalued PE

-13.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.94

Current EV/EBITDA

-22.00

Overvalued EV/EBITDA

0.87

Undervalued EV/EBITDA

-12.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

11.21

Current PS

36.99

Overvalued PS

18.34

Undervalued PS

4.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CV News & Events

Events Timeline

No data

News

2.0

12-11Benzinga

Major Stocks Including Oxford Industries, Ur-Energy, and Oracle Decline in Thursday's Pre-Market Trading

2.0

12-11Benzinga

What Caused CapsoVision's (CV) 53% Increase in After-Hours Trading?

9.5

11-13NASDAQ.COM

CapsoVision Reports Increased Q3 Loss Due to Rising Operating Expenses

People Also Watch

Frequently Asked Questions

What is CapsoVision Inc (CV) stock price today?

The current price of CV is 13.79 USD — it has increased 7.32 % in the last trading day.

What is CapsoVision Inc (CV)'s business?

CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.

What is the price predicton of CV Stock?

What is CapsoVision Inc (CV)'s revenue for the last quarter?

CapsoVision Inc revenue for the last quarter amounts to 3.54M USD, increased 19.29 % YoY.

What is CapsoVision Inc (CV)'s earnings per share (EPS) for the last quarter?

CapsoVision Inc. EPS for the last quarter amounts to -0.17 USD, increased 30.77 % YoY.

What changes have occurred in the market's expectations for CapsoVision Inc (CV)'s fundamentals?

The market is revising Downward the revenue expectations for CapsoVision, Inc. (CV) for FY2025, with the revenue forecasts being adjusted by -1.76% over the past three months. During the same period, the stock price has changed by 218.48%.

How many employees does CapsoVision Inc (CV). have?

CapsoVision Inc (CV) has 90 emplpoyees as of December 15 2025.

What is CapsoVision Inc (CV) market cap?

Today CV has the market capitalization of 601.94M USD.